Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which the Directors believe enables it to develop multiple products faster and more cost effectively than the traditional biotech model. Poolbeg Pharma has aspirations to become a “one-stop shop” for Big Pharma seeking mid-stage products to license or acquire.
Incorporated in March 2021, and headquartered in London, Poolbeg Pharma is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing and exciting markets with expected market value of $250bn by 2025.
The company was formed following a strategic decision by Open Orphan plc to demerge certain development assets from its core services led business, centred around vaccine and antiviral testing using human challenge clinical trials.
Having previously worked with Poolbeg Pharma and their Nominated Adviser and Joint Broker finnCap with the production of their AIM admission document in July last year, the Perivan shareholder communications team were delighted to help them with a further stage of their corporate journey by designing and producing their inaugural annual report which was successfully published on 9th March 2022.
Perivan specialise in the production and publication of financial documents relating to shareholder and investor communications for quoted companies, private companies and open and closed-ended funds.